Data:AXA/2025/FY/Earnings presentation (press).json: Difference between revisions
Content deleted Content added
Section records derived from the published summary page (36 sections) |
Section records derived from the published summary page (36 sections) |
||
| (One intermediate revision by the same user not shown) | |||
Line 104:
"Underlying earnings per share"
],
"content": "* REVENUES\n* {{t|€116bn|p1abw4-yxjw}}\n* {{t|+6%|p1abw4-yutx}} vs {{t|FY24|p1abw4-ndok|Full year 2024}}\n* {{t|UNDERLYING EARNINGS||Underlying earnings}}\n* {{t|€8.4bn|p1abw4-oasi}}\n* {{t|+6%|p1abw4-xtf8}} vs {{t|FY24|p1abw4-3bra|Full year 2024}}\n* {{t|+9%|p1abw4-z72l}} Excl. {{t|AXA IM|p1abw4-9cne|AXA Investment Managers}}\n* {{t|UEPS|p1abw4-5ldr|Underlying earnings per share}}\n* {{t|€3.86|p1abw4-l996}}\n* {{t|+8%|p1abw4-dpes}} vs {{t|FY24|p1abw4-ul38|Full year 2024}}\n* {{t|DIVIDEND|p1abw4-d0x9|Dividend}}(1)(footnote: See glossary for terminologies and footnotes on page 36 \u0026 37 of this document.)\n* {{t|€2.32|p1abw4-1cs9}}\n* {{t|+8%|p1abw4-idom}} vs {{t|FY24|p1abw4-eqyj|Full year 2024}}\n* SOLVENCY II RATIO\n* {{t|224%|p1abw4-ts7x}}\n* {{t|+9pts|p1abw4-t41o}} {{t|FY25|p1abw4-f4de|Full year 2025}}\n\n(1) See glossary for terminologies and footnotes on page 36 \u0026 37 of this document."
},
{
Line 129:
"Underlying earnings"
],
"content": "**GROSS WRITTEN PREMIUMS \u0026 OTHER REVENUES, UNDERLYING EARNINGS, and COMBINED RATIO by business line.**\n\n| {{t\\|Business Line\\|\\|Business mix}} | {{t\\|GROSS WRITTEN PREMIUMS \u0026 OTHER REVENUES\\|\\|Gross written premiums \u0026 other revenues}} | {{t\\|UNDERLYING EARNINGS\\|\\|Underlying earnings}} | COMBINED RATIO |\n| --- | --- | --- | --- |\n| {{t\\|P\u0026C\\|p1abw4-b57v\\|Property \u0026 casualty}} | {{t\\|€58.0bn\\|p1abw4-jqov}} {{t\\|+5%\\|p1abw4-pawh}} vs {{t\\|FY24\\|\\|Full year 2024}} | {{t\\|€5.9bn\\|p1abw4-1m4z}} {{t\\|+9%\\|p1abw4-0iy6}} vs {{t\\|FY24\\|\\|Full year 2024}} | {{t\\|90.6%\\|p1abw4-v9el}} vs {{t\\|91.0%\\|p1abw4-dwya}} {{t\\|FY24\\|\\|Full year 2024}} |\n| LIFE | {{t\\|€37.5bn\\|p1abw4-qrrm}} {{t\\|+9%\\|p1abw4-0iy6}} vs {{t\\|FY24\\|\\|Full year 2024}} | {{t\\|€2.7bn\\|p1abw4-j8uf}} {{t\\|+4%\\|p1abw4-z85f}} vs {{t\\|FY24\\|\\|Full year 2024}} | — |\n| HEALTH | {{t\\|€19.0bn\\|p1abw4-okof}} {{t\\|+5%\\|p1abw4-bxk2}} vs {{t\\|FY24\\|\\|Full year 2024}} | {{t\\|€0.8bn\\|p1abw4-xr40}} {{t\\|+17%\\|p1abw4-4l05}} vs {{t\\|FY24\\|\\|Full year 2024}} | {{t\\|97.9%\\|p1abw4-w1gu}} vs {{t\\|98.1%\\|p1abw4-mae8}} {{t\\|FY24\\|\\|Full year 2024}} |\n\n* See glossary for terminologies and footnotes on page 36 \u0026 37 of this document."
},
{
Line 365:
"Full year 2025"
],
"content": "In Euro billion\n\n**LIFE GWP \u0026 OTHER REVENUES.**\n\n| In Euro billion | {{t\\|FY24\\|p1abw4-votc\\|Full year 2024}} | {{t\\|FY25\\|
},
{
| |||